Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug ease nerve pain? new study tests acarbose with smart glucose monitoring

NCT ID NCT07436585

Symptom relief Sponsor: Shifa International Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the diabetes drug acarbose, adjusted using continuous glucose monitoring (CGM), can reduce pain in adults with painful diabetic neuropathy. 170 participants with type 2 diabetes and high blood sugar swings were enrolled. The goal was to see if controlling blood sugar spikes with acarbose could lower daily pain scores over 4 weeks compared to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

170 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Age 18-75 years. * Type 2 diabetes ≥1 year; HbA1c 7.0-10.0% within 8 weeks of randomization. * Painful DPN meeting clinical criteria; average daily pain NRS ≥4 during run-in. * High CGM variability on 7-10 day run-in (e.g., MAGE \>50 mg/dL). * Stable analgesic regimen ≥4 weeks pre-baseline. * Able to use CGM and ePRO; provides informed consent. Exclusion: * Type 1 diabetes; non-diabetic neuropathies. * Contraindications to acarbose (e.g., chronic intestinal malabsorption, inflammatory bowel disease). * eGFR \<45 mL/min/1.73 m²; significant hepatic disease (ALT/AST \>3× ULN). * Use of α-glucosidase inhibitors within 3 months. * Recent change (\<3 months) in GLP-1/GIP agonists, SGLT2i, or basal/bolus insulin strategy. * Pregnancy/lactation; other conditions compromising safety/assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diabetes Complications diabetes mellitus diabetic neuropathy Pain type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Diabetes complications Diabetic neuropathy

Contacts and locations

Locations

  • Shifa International hospital

    Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.